These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9629983)

  • 1. Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis.
    Peltroche-Llacshuanga H; Kentrup H; Haase G
    Eur J Clin Microbiol Infect Dis; 1998 Feb; 17(2):132-4. PubMed ID: 9629983
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone.
    Kanellopoulou M; Pournaras S; Iglezos H; Skarmoutsou N; Papafrangas E; Maniatis AN
    Eur J Clin Microbiol Infect Dis; 2004 Apr; 23(4):336-9. PubMed ID: 15024624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological typing of Alcaligenes xylosoxidans subsp. xylosoxidans by antibacterial susceptibility testing, fatty acid analysis, PAGE of whole-cell protein and pulsed-field gel electrophoresis.
    Knippschild M; Ansorg R
    Zentralbl Bakteriol; 1998 Jul; 288(1):145-57. PubMed ID: 9728414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
    Saiman L; Chen Y; Tabibi S; San Gabriel P; Zhou J; Liu Z; Lai L; Whittier S
    J Clin Microbiol; 2001 Nov; 39(11):3942-5. PubMed ID: 11682511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation.
    Moissenet D; Baculard A; Valcin M; Marchand V; Tournier G; Garbarg-Chenon A; Vu-Thien H
    Clin Infect Dis; 1997 Feb; 24(2):274-5. PubMed ID: 9114166
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.
    Krzewinski JW; Nguyen CD; Foster JM; Burns JL
    J Clin Microbiol; 2001 Oct; 39(10):3597-602. PubMed ID: 11574579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.
    Liu L; Coenye T; Burns JL; Whitby PW; Stull TL; LiPuma JJ
    J Clin Microbiol; 2002 Apr; 40(4):1210-3. PubMed ID: 11923333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging microorganisms in cystic fibrosis.
    Fabbri A; Tacchella A; Manno G; Viscoli C; Palmero C; Gargani GF
    Chemioterapia; 1987 Feb; 6(1):32-7. PubMed ID: 3103930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction.
    Dunne WM; Maisch S
    Clin Infect Dis; 1995 Apr; 20(4):836-41. PubMed ID: 7795082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapatient diversity of Achromobacter spp. involved in chronic colonization of Cystic Fibrosis airways.
    Dupont C; Michon AL; Jumas-Bilak E; Nørskov-Lauritsen N; Chiron R; Marchandin H
    Infect Genet Evol; 2015 Jun; 32():214-23. PubMed ID: 25791931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of polymerase chain reaction and pulsed-field gel electrophoresis for the epidemiological typing of Alcaligenes xylosoxidans subsp. xylosoxidans in a burn unit.
    Lin YH; Liu PY; Shi ZY; Lau YJ; Hu BS
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):173-8. PubMed ID: 9327244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcaligenes xylosoxidans bacteremia: clinical features and microbiological characteristics of isolates.
    Tsay RW; Lin LC; Chiou CS; Liao JC; Chen CH; Liu CE; Young TG
    J Microbiol Immunol Infect; 2005 Jun; 38(3):194-9. PubMed ID: 15986070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achromobacter xylosoxidans isolated from the sputum of a patient with cystic fibrosis mutation I1234V with Pseudomonas aeruginosa.
    Abdul Wahab A; Janahi IA; El-Shafie SS
    Saudi Med J; 2004 Jun; 25(6):810-1. PubMed ID: 15195220
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.
    Vu-Thien H; Moissenet D; Valcin M; Dulot C; Tournier G; Garbarg-Chenon A
    Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):876-9. PubMed ID: 8997562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance and identification of uncommon Gram-negative bacteria isolated from sputum of adult patients with cystic fibrosis.
    Gillow C; Shaw A; Moore JE; Elborn JS; Murphy PG
    Br J Biomed Sci; 2006; 63(1):22-5. PubMed ID: 16613138
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics of Alcaligenes odorans var. viridans isolated from human sources.
    Gilardi GL
    Can J Microbiol; 1967 Jul; 13(7):895-900. PubMed ID: 6036895
    [No Abstract]   [Full Text] [Related]  

  • 17. [The genus Alcaligenes faecalis and its implication in infectious pathology].
    Bergner E; Mărgineanu C
    Microbiol Parazitol Epidemiol (Bucur); 1972; 17(3):231-7. PubMed ID: 5035829
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.
    Talbot NP; Flight WG
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():27-9. PubMed ID: 27374622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achromobacter xylosoxidans n. sp. from human ear discharge.
    Yabuuchi E; Oyama A
    Jpn J Microbiol; 1971 Sep; 15(5):477-81. PubMed ID: 5316576
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.